Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Digestive Diseases and Sciences

• Publication date

  2013-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10620-012-2484-xPMID 23187978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New Protease Inhibitors for the Treatment of Chronic Hepatitis C

  2012cited by this paper
• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cited by this paper
• Response-guided telaprevir combination treatment for hepatitis C virus infection.

  2011cited by this paper
• Limited use of interleukin 28B in the setting of response‐guided treatment with detailed on‐treatment virological monitoring

  2011cited by this paper
• Telaprevir for previously untreated chronic hepatitis C virus infection.

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• Hepatitis C treatment among racial and ethnic groups in the IDEAL trial

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• The role of genetic markers in hepatitis C virus therapy: a major step for individualized care

  2011cited by this paper
• Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

  2011cited by this paper
• Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

  2011cited by this paper
• Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future

  2011cited by this paper
• Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

  2010cited by this paper
• Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

  2010cited by this paper
• Randomized trial of peginterferon alfa‐2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

  2010cited by this paper
• Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

  2010cited by this paper
• Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin

  2010cited by this paper
• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

  2010cited by this paper
• Virologic response rates of weight‐based taribavirin versus ribavirin in treatment‐naive patients with genotype 1 chronic hepatitis C

  2010cited by this paper
• Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

  2010cited by this paper
• Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

  2010cited by this paper
• Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population

  2010cited by this paper
• Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.

  2010cited by this paper
• Identifying and Quantifying Heterogeneity

  2009cited by this paper
• Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

  2009cited by this paper
• Impact of high‐dose peginterferon alfa‐2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial

  2009cited by this paper
• A Randomized Study of Extended Treatment With Peginterferon α-2b Plus Ribavirin Based on Time to HCV RNA Negative–Status in Patients With Genotype 1b Chronic Hepatitis C

  2009cited by this paper
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

  2009cited by this paper
• Peginterferon alfa‐2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub‐sets of older and younger HCV genotype 1 patients

  2009cited by this paper
• Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.

  2009cited by this paper
• Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

  2009cited by this paper
• A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment‐naïve patients with chronic hepatitis C: ViSER1 results

  2009cited by this paper
• Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

  2009cited by this paper
• Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices

  2009cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009cited by this paper
• Short‐term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response

  2009cited by this paper
• Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

  2008cited by this paper
• Pegylated α‐interferon‐2a plus ribavirin compared with pegylated α‐interferon‐2b plus ribavirin for initial treatment of chronic hepatitis C virus: Prospective, non‐randomized study

  2008cited by this paper
• Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

  2008cited by this paper
• Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

  2008cited by this paper
• Improved outcomes in patients with hepatitis C with difficult‐to‐treat characteristics: Randomized study of higher doses of peginterferon α‐2a and ribavirin

  2008cited by this paper
• The use of different Peg‐interferon α‐2b regimens plus ribavirin in HCV‐1b‐infected patients after rapid virological response does not affect the achievement of sustained virological response

  2008cited by this paper
• Early virologic response after peginterferon alpha‐2a plus ribavirin or peginterferon alpha‐2b plus ribavirin treatment in patients with chronic hepatitis C *

  2007cited by this paper
• Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

  2007cited by this paper
• Clinical trial: comparison of weekly once versus twice half‐dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV‐1 positive patients with chronic hepatitis C

  2007cited by this paper
• The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α‐2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

  2006cited by this paper
• Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data.

  2006cited by this paper
• Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

  2006cited by this paper
• Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy

  2006cited by this paper
• Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

  2006cited by this paper
• Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

  2006cited by this paper
• Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.

  2006cited by this paper
• Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

  2005cited by this paper
• Peginterferon alfa‐2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Advanced methods in meta‐analysis: multivariate approach and meta‐regression

  2002cited by this paper
• Quantifying heterogeneity in a meta‐analysis

  2002cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

  1998cited by this paper
• Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Quantitative methods in the review of epidemiologic literature.

  1987cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Assessment of baseline pretreatment factors and on‐treatment virological response to predict sustained virological response in patients with chronic hepatitis C treated with pegylated interferon and ribavirin

  2017cites this paper
• Tract cost-effectiveness model to personalize antiviral therapy in naive atients with genotype 1 chronic hepatitis

  2015cites this paper
• A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.

  2015cites this paper
• The future of dual therapy for hepatitis C virus

  2014cites this paper
• Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.

  2014cites this paper
• Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C

  2014cites this paper
• An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

  2014cites this paper
• [The value of genetics in the era of hepatitis C triple therapy].

  2014cites this paper
• Background: Achievement of early viral suppression is important in patients with chronic HCV infection treated with telaprevir (TLV) or boceprevir (BOC) to avoid selection

  2013cites this paper
• Triple Combination Therapy for Hepatitis C with Telaprevir Exhibits Greater Early Antiviral Activity than with Boceprevir

  2013cites this paper